City Therapeutics, an early-stage developer of RNAi-based drugs, raised $200 million in a US initial public offering priced at the mid-point of its marketed range.
CITY THERAPEUTICS PRICES UPSIZED IPO AT $18 A SHARE, RAISING ABOUT $200 MILLION
The RNAi drug developer sold 11.1M shares and is expected to begin trading on Nasdaq on Oct. 16 under $CTY, with Goldman Sachs, Jefferies and Stifel among the bookrunners, per the company
City lights on. Charts can wait. 🌃✨
Time to slow down and enjoy the night. 😌💙
What's your night vibe?
☕ Coffee
🎧 Music
📱 One last chart check 👀
😴 Straight to bed
Drop your pick below 👇
#MEXC# #GoodNight# #CryptoLife#